Sunitinib is the first line cytokine therapy in good risk treatment naive metastatic kidney cancer providing a 6 month progression free survival benefit over IFN

Sunitinib is the first line cytokine therapy in good risk treatment naive metastatic kidney cancer providing a 6 month progression free survival benefit over IFN

This randomized phase 3 trial of 750 patients with metastatic kidney cancer compared 4 weeks of 50 mg orally daily for 4 weeks (then a 2 week off period) of sunitinib to IFN and found that sunitinib had a significantly better progression free survival rate of 11 v 5 months. Fatigue was more common in IFN group. Diarrhea, vomiting, high blood pressure and hand-foot syndrome were more common in sunitinib group. The median duration of sunitinib treatment was 6 months. For side effects the dose was reduced. Sunitinib is the first line cytokine agent in treatment naïve good risk patients and mainly for clear cell pathology.

Start typing and press Enter to search